$19.1M
+$19.1M this year1 filing since 2026 · latest Equity filed
Rapalogix Health is a Carlsbad, California biopharma company applying cellular longevity science to skin health. It develops physician-dispensed professional skincare and a pipeline of prescription dermatology therapeutics built around selective modulation of the TORC1/mTOR pathway in skin. Its first commercial brand, Re-Q Health, launched into U.S. dermatology and aesthetic practices, and the company raised a $20 million Series A in June 2026 co-led by Woodline Partners LP and GordonMD Global Investments LP. The company was co-founded by skin longevity scientist Rahul Mehta, PhD, dermatologist Doris Day, MD, and healthcare executive Brent Saunders.
What sets it apart
Targets the biology of skin aging through selective TORC1 pathway modulation with a patented compound (RLX-201), rather than treating surface symptoms, and sells through dermatology and aesthetic practices instead of retail.
The first product from Re-Q Health, Rapalogix's professional skincare brand, powered by the company's pro-longevity compound RLX-201 and available at dermatology and aesthetic practices in the United States.
